1. Смирнов А.В., Есаян А.М., Каюков И.Г. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6 (4): 11-17 (Smirnov A.V., Esajan A.M., Kajukov I.G. Hronicheskaja bolezn’ pochek: na puti k edinstvu predstavlenij. Nefrologija 2002; 6 (4): 11-17)
2. Смирнов А.В., Добронравов В.А., Каюков И.Г. и др. Эпидемиология и социально-экономические аспекты хронической болезни почек. Нефрология 2006; 10 (1): 7-13 [Smirnov A.V., Dobronravov V.A., Kajukov I.G. i dr. Jepidemiologija i social’nojekonomicheskie aspekty hronicheskoj bolezni pochek. Nefrologija 2006; 10 (1): 7-13]
3. Смирнов А.В., Добронравов В.А., Каюков И.Г. и др. Рекомендации Научно-исследовательского института нефрологии Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова: определение, классификация, диагностика и основные направления профилактики хронической болезни почек у взрослых. Левша, СПб, 2008; 51 [Smirnov A.V., Dobronravov V.A., Kajukov I.G. i dr. Rekomendacii Nauchno-issledovatel’skogo instituta nefrologii Sankt-Peterburgskogo gosudarstvennogo medicinskogo universiteta im. akad. I.P. Pavlova: opredelenie, klassifikacija, diagnostika i osnovnye napravlenija profilaktiki hronicheskoj bolezni pochek u vzroslyh. Levsha, SPb, 2008; 51]
4. Смирнов А.В., Добронравов В.А., Каюков И.Г. и др. Проблема модификации классификации хронической болезни почек. Нефрология 2010; 15(2): 7-15 [Smirnov A.V., Dobronravov V.A., I.G. i dr. Problema modifikacii klassifikacii hronicheskoj bolezni pochek. Nefrologija 2010; 15(2): 7-15]
5. Greenbaum L.A. Anemia in Chronic Renal Disease. In: Geary D.F., Schaefer F., eds. Comprehensive pediatric nephrology. Mosby Elsevier, Philadelphia, 2008; 761-772
6. Atkinson M.A., Furth S.L. Anemia in children with chronic kidney disease. Nat Rev Nephrol 2011; 7: 635-641
7. Koshy S.M., Geary D.F. Anemia in children with chronic kidney disease. Pediatr Nephrol. 2008; 23: 209-219
8. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Inter. Suppl 2012; 2: 331-335
9. Практические клинические рекомендации KDIGO по анемии при хронической болезни почек 2012. Нефрология и диализ 2012; 15 (1): 14-53 [Prakticheskie klinicheskie rekomendacii KDIGO po anemii pri hronicheskoj bolezni pochek 2012. Nefrologija i dializ. 2012; 15 (1): 14-53]
10. The National Institute for Health and Clinical Excellence (NICE). National costing report: anaemia management in people with CKD. Implementing NICE guidance in England. Issued: February 2011. This updates and replaces NICE clinical guideline 39
11. K/DOQI; National Kidney Foundation III Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Children. Am J Kidney Dis. 2006; 47 (3): 86-108
12. Эттингер О.А., Зеновко И.К., Гендин Т.Е. Анемия при хронической болезни почек: роль препаратов железа. Лечебное дело 2012; 4: 38-46 [Jettinger O.A., Zenovko I.K., Gendin T.E. Anemija pri hronicheskoj bolezni pochek: rol’ preparatov zheleza. Lechebnoe delo 2012; 4: 38-46]
13. Albaramki J., Hodson E.M., Craig J.C., Webster A.C. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2012 Jan 18; 1: CD 007857.doi
14. Warady B.A., Kausz A., Lerner G. et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 2004; 19 (6): 655-661
15. Rozen-Zvi B., Gafter-Gvili A., Paul M., Leibovici L., Shpilberg O., Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008; 52 (5): 897-906
16. Morgan H.E., Holt R.C., Jones C.A., Judd B.A. Intravenous iron treatment in paediatric chronic kidney disease patients not on erythropoietin Pediatr Nephrol 2007; 22 (11): 1963-1965
17. Моисеев С.В. Железа карбоксимальтозат (Феринжект®) - новый внутривенный препарат для лечения железодефицитной анемии. Клиническая фармакология и терапия 2012; 21 (2): 2-7 [Moiseev S.V. Zheleza karboksimal'tozat (Ferinzhekt®) - novyj vnutrivennyj preparat dlja lechenija zhelezodeficitnoj anemii. Klinicheskaja farmakologija i terapija 2012; 21 (2): 2-7]
18. Warady B.A., Zobrist R.H., Finan E. Sodium ferric gluconate complex maintenance therapy in children on hemodialysis. Pediatr Nephrol 2006; 21 (4): 553-560
19. Goldstein S.L., Morris D., Warady B.A. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial. Am J Kidney Dis 2013; 61 (4): 588- 597
20. Moorani K.N., Asim S. Parenteral iron sucrose in iron deficiency anaemia of paediatric chronic kidney disease. J Ayub Med Coll Abbottabad 2011; 23 (3): 47-50
21. Van Buren P., Velez R.L., Vaziri N.D., Zhou X.J. Ironoverdose: a contributor to adverse outcomes in randomized trials of anemia correction inCKD. Int Urol Nephrol. 2012; 44 (2): 499-507
22. Geisser Р. The pharmacology and safety profile of ferric carboxymaltose (Ferinject ®): structure/reactivity relationships of iron preparations. Port. J. Nephrol. Hypert 2009 ; 23 (1): 11-16
23. Warady B.A., Zobrist R.H., Wu J., Finan E. Ferrlecit Pediatric Study Group. Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol. 2005; 20: 1320-1327
24. Morgan H.E., Gautam M., Geary D.F. Maintenance intravenous iron therapy in pediatric hemodialysis patients. Pediatr Nephrol 2001; 16: 779-783
25. Warady B.A., Silverstein D.M. Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatr Nephrol 2014; 29 (9): 1493-1505
26. Bamgbola O.F., Kaskel F.J., Coco M. Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol. 2009; 24: 571-579
27. De Palo T., Giordano M., Palumbo F. et al. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol. 2004; 19 (3): 337-340
28. Шило В.Ю. Новый эритропоэз-стимулирующий препарат Аранесп (дарбэпоэтин альфа) в коррекции анемии почечного генеза Рабочая группа по анемии (РГА); Центр диализа при ГКБ № 20, г. Москва. Нефрология и диализ 2007, 9 (3): 216-223 [Shilo V.Ju. Novyj jeritropojez-stimulirujushhij preparat Aranesp (darbjepojetin al’fa) v korrekcii anemii pochechnogo geneza Rabochaja gruppa po anemii (RGA); Centr dializa pri GKB № 20, g. Moskva. Nefrologija i dializ 2007, 9 (3): 216-223]
29. Schmitt C.P., Nau B., Brummer C., Rosenkranz J., Schaefer F. Increased injection pain with darbepoetin-alpha compared to epoetin-beta in paediatric dialysis patients. Nephrol. Dial. Transplant 2006; 21: 3520-3524
30. Hattori M., Uemura O., Hataya H., Ito S., Hisano M., Ohta T., Fujinaga S., Kise T., Gotoh Y., Matsunaga A., Ito N., Akizawa T.; The KRN321 Pediatric Study Group. Efficacy and safety of darbepoetin alfa for anemia in children with chronic kidney disease: a multicenter prospective study in Japan. Clin Exp Nephrol. 2014; 18 (4): 634- 6 41
31. Can C., Emre S., Bilge I., Yilmaz A., Şirin A. Comparison of recombinant human erythropoietin and darbepoetin alpha in children. Pediatr Int. 2013; 55(3): 296-299
32. Лысова. Е.В., Савенкова Н.Д. Особенности синдрома анемии при хронической болезни почек у детей. Нефрология 2014, 18(3): 34-44 [Lysova. E.V., Savenkova N.D. Osobennosti sindroma anemii pri hronicheskoj bolezni pochek u detej. Nefrologija 2014, 18(3): 34-44]
33. Nangaku M., Eckardt K.U. Hypoxia and the HIF system in kidney disease. J Mol Med.2007; 85(12): 1325-1330